Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 for Stem Cell Mobilization in Hematologic Malignancies (Phase II)
ChiCTR2600122865Phase 2Recruiting
- Sponsor
- Shandong First Medical University
- Start
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of romiplostim in multiple myeloma (MM), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL) and 1 more (4 arms), sponsored by Shandong First Medical University. Primary endpoint: Proportion of patients achieving peripheral blood CD34+ cell count >=20/μL. Started Apr 2026; status: recruiting.
02
Drugs
romiplostim
03
Conditions
multiple myeloma (MM)non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)hematopoietic malignancies
Beyond the preview
Go deeper on ChiCTR2600122865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122865.